Open Access

Development of c‑MET‑specific chimeric antigen receptor‑engineered natural killer cells with cytotoxic effects on human liver cancer HepG2 cells

  • Authors:
    • Bing Liu
    • Zheng‑Zhi Liu
    • Mei‑Ling Zhou
    • Jian‑Wei Lin
    • Xue‑Mei Chen
    • Zhu Li
    • Wen‑Bin Gao
    • Zhen‑Dong Yu
    • Tao Liu
  • View Affiliations

  • Published online on: July 25, 2019     https://doi.org/10.3892/mmr.2019.10529
  • Pages: 2823-2831
  • Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

In recent years, cellular immunotherapy has served an important role in the combined treatment of hepatocellular carcinoma. The possibility of specific cell therapies for the treatment of solid tumours has been further explored following the success of chimeric antigen receptor (CAR)‑T cell therapy in the treatment of haematological tumours. The present study aimed to evaluate the specificity and efficiency of c‑MET‑targeted CAR‑NK cell immunotherapy on human liver cancer in vitro. A CAR structure that targeted and recognised a c‑MET antigen was constructed. c‑MET‑CAR was transferred into primary NK cells using lentiviral infection. c‑MET‑positive HepG2 cells were used as an in vitro study model. The cytotoxicity assay results revealed that c‑MET‑CAR‑NK cells exhibited more specific cytotoxicity for HepG2 cells with high c‑MET expression compared with the lung cancer cell line H1299, which has low levels of c‑MET expression. The results of the present study demonstrated that c‑MET may be a specific and effective target for human liver cancer cell CAR‑NK immunotherapy. Based on these results, CAR‑NK cell‑based immunotherapy may provide a potential biotherapeutic approach for liver cancer treatment in the future.
View Figures
View References

Related Articles

Journal Cover

September-2019
Volume 20 Issue 3

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Liu B, Liu ZZ, Zhou ML, Lin JW, Chen XM, Li Z, Gao WB, Yu ZD and Liu T: Development of c‑MET‑specific chimeric antigen receptor‑engineered natural killer cells with cytotoxic effects on human liver cancer HepG2 cells. Mol Med Rep 20: 2823-2831, 2019
APA
Liu, B., Liu, Z., Zhou, M., Lin, J., Chen, X., Li, Z. ... Liu, T. (2019). Development of c‑MET‑specific chimeric antigen receptor‑engineered natural killer cells with cytotoxic effects on human liver cancer HepG2 cells. Molecular Medicine Reports, 20, 2823-2831. https://doi.org/10.3892/mmr.2019.10529
MLA
Liu, B., Liu, Z., Zhou, M., Lin, J., Chen, X., Li, Z., Gao, W., Yu, Z., Liu, T."Development of c‑MET‑specific chimeric antigen receptor‑engineered natural killer cells with cytotoxic effects on human liver cancer HepG2 cells". Molecular Medicine Reports 20.3 (2019): 2823-2831.
Chicago
Liu, B., Liu, Z., Zhou, M., Lin, J., Chen, X., Li, Z., Gao, W., Yu, Z., Liu, T."Development of c‑MET‑specific chimeric antigen receptor‑engineered natural killer cells with cytotoxic effects on human liver cancer HepG2 cells". Molecular Medicine Reports 20, no. 3 (2019): 2823-2831. https://doi.org/10.3892/mmr.2019.10529